BR112018011203A2 - terapia de combinação para câncer - Google Patents

terapia de combinação para câncer

Info

Publication number
BR112018011203A2
BR112018011203A2 BR112018011203A BR112018011203A BR112018011203A2 BR 112018011203 A2 BR112018011203 A2 BR 112018011203A2 BR 112018011203 A BR112018011203 A BR 112018011203A BR 112018011203 A BR112018011203 A BR 112018011203A BR 112018011203 A2 BR112018011203 A2 BR 112018011203A2
Authority
BR
Brazil
Prior art keywords
cancer
patient
combination therapy
compound
formula
Prior art date
Application number
BR112018011203A
Other languages
English (en)
Inventor
Karis Lin Aimee
Paul Donoho Gregory
Paul BECKMANN Richard
WACHECK Volker
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112018011203A2 publication Critical patent/BR112018011203A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção refere-se a um método de tratamento de cânceres de histologia escamosa, câncer de mama, câncer de próstata, câncer de bexiga, câncer cervical, câncer endometrial, câncer ovariano, e câncer colorretal em um paciente, compreendendo a administração a um paciente em necessidade de tal tratamento uma quantidade eficaz de um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo; em combinação com uma quantidade eficaz de um composto de fórmula (ii) ou um sal farmaceuticamente aceitável do mesmo.
BR112018011203A 2015-12-15 2016-12-08 terapia de combinação para câncer BR112018011203A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267462P 2015-12-15 2015-12-15
PCT/US2016/065503 WO2017105982A1 (en) 2015-12-15 2016-12-08 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
BR112018011203A2 true BR112018011203A2 (pt) 2018-11-21

Family

ID=57590897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011203A BR112018011203A2 (pt) 2015-12-15 2016-12-08 terapia de combinação para câncer

Country Status (15)

Country Link
US (1) US20180228795A1 (pt)
EP (1) EP3389660B1 (pt)
JP (1) JP6359197B2 (pt)
KR (1) KR20180081580A (pt)
CN (1) CN108472293A (pt)
AU (1) AU2016370297A1 (pt)
BR (1) BR112018011203A2 (pt)
CA (1) CA3005358A1 (pt)
EA (1) EA201891005A1 (pt)
HK (1) HK1254687A1 (pt)
IL (1) IL259097A (pt)
MX (1) MX2018007225A (pt)
NZ (1) NZ742470A (pt)
SG (1) SG11201803903YA (pt)
WO (1) WO2017105982A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
EP2640386B1 (en) * 2010-11-16 2017-01-18 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
JO3003B1 (ar) * 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013103836A2 (en) 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
WO2017105982A1 (en) 2017-06-22
JP2018502873A (ja) 2018-02-01
CN108472293A (zh) 2018-08-31
KR20180081580A (ko) 2018-07-16
EA201891005A1 (ru) 2018-12-28
EP3389660A1 (en) 2018-10-24
MX2018007225A (es) 2018-08-01
SG11201803903YA (en) 2018-06-28
IL259097A (en) 2018-06-28
CA3005358A1 (en) 2017-06-22
AU2016370297A1 (en) 2018-05-24
NZ742470A (en) 2019-09-27
EP3389660B1 (en) 2019-10-16
HK1254687A1 (zh) 2019-07-26
JP6359197B2 (ja) 2018-07-18
US20180228795A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
MX2021003389A (es) Metodos para tratar el cancer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MA39906A (fr) Polythérapies pour le traitement du cancer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
PH12016502354A1 (en) Pharmaceutical composition
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
PH12015502342A1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112018075660A2 (pt) métodos de tratamento de câncer de pâncreas
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL281439A (en) Combined treatment for blood cancer
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
IL281281A (en) Combined treatment for prostate cancer
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
BR112018011203A2 (pt) terapia de combinação para câncer
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]